Abcellera Biologics Company Leadership
| ABCL Stock | USD 2.44 0.06 2.52% |
Abcellera Biologics employs about 596 people. The company is managed by 22 executives with a total tenure of roughly 1391 years, averaging almost 63.0 years of service per executive, having 27.09 employees per reported executive. Inspection of Abcellera Biologics' management performance can provide insight into the company performance.
Abcellera |
Abcellera Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1241) % which means that it has lost $0.1241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1475) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Abcellera Biologics Workforce Comparison
Abcellera Biologics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 6,321. Abcellera Biologics holds roughly 596 in number of employees claiming about 9% of equities under Health Care industry.
Abcellera Biologics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abcellera Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abcellera Biologics Notable Stakeholders
An Abcellera Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abcellera Biologics often face trade-offs trying to please all of them. Abcellera Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abcellera Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Carl Hansen | President CEO | Profile | |
| Graham MSc | Director Development | Profile | |
| Andy Clark | Head Assurance | Profile | |
| Veronique Lecault | COO Director | Profile | |
| Bo Barnhart | Scientific Director | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| EdD CEC | Senior Development | Profile | |
| Paul Colussi | Site Technologies | Profile | |
| JD Esq | Chief Officer | Profile | |
| Murray McCutcheon | Senior Partnering | Profile | |
| M CIPD | Sr Culture | Profile | |
| Ester Falconer | Chief Officer | Profile | |
| Alexandra MSc | Ma Communications | Profile | |
| Esq JD | CCO, Officer | Profile | |
| Janna Bednenko | Head Genetics | Profile | |
| Josephine Hellschlienger | Manager Relations | Profile | |
| Adam MAICD | Senior Discovery | Profile | |
| ChB MB | Senior Development | Profile | |
| Tiffany BSc | Vice Communications | Profile | |
| Neil MBA | Chief Officer | Profile | |
| CGA CPA | Senior Accounting | Profile | |
| Kathleen BA | Head Communications | Profile |
About Abcellera Biologics Management Performance
The success or failure of an entity such as Abcellera Biologics often depends on how effective the management is. Abcellera Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abcellera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abcellera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States.
Abcellera Biologics Workforce Analysis
Traditionally, organizations such as Abcellera Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abcellera Biologics within its industry.Abcellera Biologics Manpower Efficiency
Return on Abcellera Biologics Manpower
| Revenue Per Employee | 48.4K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 273.2K | |
| Net Loss Per Executive | 7.4M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 30.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.